Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
2014 3
2015 1
2017 1
2018 3
2019 1
2021 1
2022 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Human airway mast cells proliferate and acquire distinct inflammation-driven phenotypes during type 2 inflammation.
Dwyer DF, Ordovas-Montanes J, Allon SJ, Buchheit KM, Vukovic M, Derakhshan T, Feng C, Lai J, Hughes TK, Nyquist SK, Giannetti MP, Berger B, Bhattacharyya N, Roditi RE, Katz HR, Nawijn MC, Berg M, van den Berge M, Laidlaw TM, Shalek AK, Barrett NA, Boyce JA. Dwyer DF, et al. Sci Immunol. 2021 Feb 26;6(56):eabb7221. doi: 10.1126/sciimmunol.abb7221. Sci Immunol. 2021. PMID: 33637594 Free PMC article.
Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
Al-Efraij K, Aljama MA, Kennecke HF. Al-Efraij K, et al. Cancer Med. 2015 Jun;4(6):864-70. doi: 10.1002/cam4.435. Epub 2015 Feb 26. Cancer Med. 2015. PMID: 25727756 Free PMC article.
Dose escalation of O-LAR was associated with improved symptom control in NET patients who were refractory to the standard dose levels. ...Retrospective review of imaging did not document any reductions in tumor volume. Higher doses of O-LAR are associated with impro …
Dose escalation of O-LAR was associated with improved symptom control in NET patients who were refractory to the standard dose levels …
TM7SF3 controls TEAD1 splicing to prevent MASH-induced liver fibrosis.
Isaac R, Bandyopadhyay G, Rohm TV, Kang S, Wang J, Pokhrel N, Sakane S, Zapata R, Libster AM, Vinik Y, Berhan A, Kisseleva T, Borok Z, Zick Y, Telese F, Webster NJG, Olefsky JM. Isaac R, et al. Cell Metab. 2024 May 7;36(5):1030-1043.e7. doi: 10.1016/j.cmet.2024.04.003. Epub 2024 Apr 25. Cell Metab. 2024. PMID: 38670107
The efficacy and safety of treatments for acute gout: results from a series of systematic literature reviews including Cochrane reviews on intraarticular glucocorticoids, colchicine, nonsteroidal antiinflammatory drugs, and interleukin-1 inhibitors.
Wechalekar MD, Vinik O, Moi JH, Sivera F, van Echteld IA, van Durme C, Falzon L, Bombardier C, Carmona L, Aletaha D, Landewé RB, van der Heijde DM, Buchbinder R. Wechalekar MD, et al. J Rheumatol Suppl. 2014 Sep;92:15-25. doi: 10.3899/jrheum.140458. J Rheumatol Suppl. 2014. PMID: 25180124 Review.
Structure-Based Design of a Monosaccharide Ligand Targeting Galectin-8.
Bohari MH, Yu X, Kishor C, Patel B, Go RM, Eslampanah Seyedi HA, Vinik Y, Grice ID, Zick Y, Blanchard H. Bohari MH, et al. ChemMedChem. 2018 Aug 20;13(16):1664-1672. doi: 10.1002/cmdc.201800224. Epub 2018 Jul 10. ChemMedChem. 2018. PMID: 29926535
Galectin-8 is a beta-galactoside-recognising protein that has a role in the regulation of bone remodelling and is an emerging new target for tackling diseases with associated bone loss. We have designed and synthesised methyl 3-O-[1-carboxyethyl]-beta-d-galactopyranoside ( …
Galectin-8 is a beta-galactoside-recognising protein that has a role in the regulation of bone remodelling and is an emerging new target for …
13 results